Lucid Diagnostics (LUCD) to Release Earnings on Thursday

Key Points

• Lucid Diagnostics will report Q1 2026 results before the market opens on Thursday, May 14 at 8:30 AM ET, with analysts forecasting EPS of ($0.05) and revenue of $1.38 million.
• The company last missed EPS (reported ($0.10) vs. estimate ($0.07)) while posting $1.50 million in revenue, and analysts now project $0 EPS for both the current and next fiscal years.
• Shares trade near $1.08 with a $210.9M market cap and a 52‑week range of $0.95–$1.70; the consensus rating is a Moderate Buy with a $4.13 average price target and ~74% institutional ownership.

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) is anticipated to release its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Lucid Diagnostics to post earnings of ($0.05) per share and revenue of $1.38 million for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 14, 2026 at 8:30 AM ET.

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.03). The company had revenue of $1.50 million during the quarter, compared to analyst estimates of $1.39 million. On average, analysts expect Lucid Diagnostics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Lucid Diagnostics Stock Performance

NASDAQ:LUCD opened at $1.08 on Thursday. The company has a market cap of $210.87 million, a PE ratio of -1.12 and a beta of 1.10. Lucid Diagnostics has a 52-week low of $0.95 and a 52-week high of $1.70. The stock has a 50-day simple moving average of $1.26 and a 200 day simple moving average of $1.19.

Analyst Ratings Changes

A number of research firms recently issued reports on LUCD. Needham & Company LLC reiterated a "buy" rating and set a $3.00 price objective on shares of Lucid Diagnostics in a report on Thursday, March 26th. Wall Street Zen upgraded Lucid Diagnostics from a "sell" rating to a "hold" rating in a report on Saturday, March 28th. Ascendiant Capital Markets increased their price objective on Lucid Diagnostics from $8.25 to $9.00 and gave the stock a "buy" rating in a report on Thursday, April 9th. Finally, BTIG Research reiterated a "buy" rating and set a $2.50 price objective on shares of Lucid Diagnostics in a report on Monday, March 30th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $4.13.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd bought a new position in Lucid Diagnostics in the fourth quarter valued at approximately $246,000. Millennium Management LLC bought a new position in Lucid Diagnostics in the fourth quarter valued at approximately $168,000. Abel Hall LLC bought a new position in Lucid Diagnostics in the fourth quarter valued at approximately $33,000. Squarepoint Ops LLC grew its stake in Lucid Diagnostics by 1,871.7% in the fourth quarter. Squarepoint Ops LLC now owns 342,883 shares of the company's stock valued at $374,000 after purchasing an additional 325,493 shares in the last quarter. Finally, Barclays PLC grew its stake in Lucid Diagnostics by 40.8% in the fourth quarter. Barclays PLC now owns 141,167 shares of the company's stock valued at $154,000 after purchasing an additional 40,891 shares in the last quarter. 74.01% of the stock is currently owned by institutional investors.

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company's flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid's CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.